Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of therapies created to treat inflammatory diseases. The company's cell-based therapies are developed to treat liver disease and autoimmunity deficiencies by targeting the regulation of NKT cells.
You’re viewing a free company profile from the PitchBook Platform. To explore GRI Bio’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Angel (individual) | Cancelled | Generating Revenue | ||||
1. Angel (individual) | 17-Apr-2015 | 00.000 | 00.000 | Completed | Generating Revenue |
Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
Abraham Van Wyk | Self | Board Member | 000 0000 | |
Albert Agro Ph.D | Self | Senior Vice President of Clinical Development, Board Member and Co-Founder | 000 0000 | |
Marc Hertz Ph.D | GRI Bio | Co-Founder, Chairman & Chief Executive Officer | 000 0000 | |
Vipin Chaturvedi Ph.D | GRI Bio | Chief Scientific Officer, Board Member and Co-Founder | 000 0000 |
1 Former Board Member
You’re viewing 4 of 5 board members. Get the full list »